Asset
FICERAFUSP ALFA
BICARA THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07807163 | phase2 | recruiting | 2026-09-01 | 2028-03-01 | Bicara Therapeutics | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC |
| NCT06788990 | phase2_3 | recruiting | 2025-01-28 | 2028-04-01 | Bicara Therapeutics | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
| NCT04429542 | phase1 | recruiting | 2020-06-01 | 2027-10-31 | Bicara Therapeutics | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.